Show simple item record

dc.contributor.authorHamed, M
dc.contributor.authorGladbach, Y
dc.contributor.authorMöller, S
dc.contributor.authorFischer, S
dc.contributor.authorErnst, M
dc.contributor.authorStruckmann, S
dc.contributor.authorStorch, A
dc.contributor.authorFuellen, G
dc.date.accessioned2020-12-10T00:35:07Z
dc.date.available2020-12-10T00:35:07Z
dc.date.issued2018-05-21
dc.identifierpii: 10.1038/s41598-018-25754-5
dc.identifier.citationHamed, M., Gladbach, Y., Möller, S., Fischer, S., Ernst, M., Struckmann, S., Storch, A. & Fuellen, G. (2018). A workflow for the integrative transcriptomic description of molecular pathology and the suggestion of normalizing compounds, exemplified by Parkinson's disease.. Sci Rep, 8 (1), pp.7937-. https://doi.org/10.1038/s41598-018-25754-5.
dc.identifier.issn2045-2322
dc.identifier.urihttp://hdl.handle.net/11343/253520
dc.description.abstractThe volume of molecular observations on human diseases in public databases is continuously increasing at accelerating rates. A bottleneck is their computational integration into a coherent description, from which researchers may derive new well-founded hypotheses. Also, the need to integrate data from different technologies (genetics, coding and regulatory RNA, proteomics) emerged in order to identify biomarkers for early diagnosis and prognosis of complex diseases and therefore facilitating the development of novel treatment approaches. We propose here a workflow for the integrative transcriptomic description of the molecular pathology in Parkinsons's Disease (PD), including suggestions of compounds normalizing disease-induced transcriptional changes as a paradigmatic example. We integrated gene expression profiles, miRNA signatures, and publicly available regulatory databases to specify a partial model of the molecular pathophysiology of PD. Six genetic driver elements (2 genes and 4 miRNAs) and several functional network modules that are associated with PD were identified. Functional modules were assessed for their statistical significance, cellular functional homogeneity, literature evidence, and normalizing small molecules. In summary, our workflow for the joint regulatory analysis of coding and non-coding RNA, has the potential to yield clinically as well as biologically relevant information, as demonstrated here on PD data.
dc.languageeng
dc.publisherSpringer Science and Business Media LLC
dc.rights.urihttps://creativecommons.org/licenses/by/4.0
dc.titleA workflow for the integrative transcriptomic description of molecular pathology and the suggestion of normalizing compounds, exemplified by Parkinson's disease.
dc.typeJournal Article
dc.identifier.doi10.1038/s41598-018-25754-5
melbourne.affiliation.departmentSurgery (RMH)
melbourne.source.titleScientific Reports
melbourne.source.volume8
melbourne.source.issue1
melbourne.source.pages7937-
dc.rights.licenseCC BY
melbourne.elementsid1366011
melbourne.openaccess.pmchttp://www.ncbi.nlm.nih.gov/pmc/articles/PMC5962550
melbourne.contributor.authorErnst, Matthias
dc.identifier.eissn2045-2322
melbourne.accessrightsOpen Access


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record